Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally adminis…
USD93.99+0.71%vs prev. close
Performance
1W
-0.22%
1M
+17.22%
3M
-5.51%
1Y
+31.86%
YTD
+18.15%
Valuation
P/E
—
EPS TTM
-14.47
Dividend yield
—
Size and risk
Market cap
$6.1B
Beta
0.74
Price history
MIRM price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Mirum Pharmaceuticals
MIRM
Biotechnology
Mkt cap (USD bn)
6.1
P/E
—
Div yld
—
1W
-0.2%
1M
+17.2%
3M
-5.5%
6M
-16.2%
1Y
+31.9%
YTD
+18.1%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Mirum Pharmaceuticals
MIRM
Biotechnology
6.1
—
—
-0.2%
+17.2%
-5.5%
-16.2%
+31.9%
+18.1%
Subscribe to Equity Analytics to compare MIRM with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.